PGDx machine learning approach outperforms existing mutation detection methods in study

(Pure Communications Inc.) Personal Genome Diagnostics, Inc. (PGDx), a leader in cancer genomics, today announced that its machine learning based technology, CerebroTM, outperformed existing methods to identify tumor-specific, or somatic mutations, enabling more accurate NGS clinical test results.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news